Related Experiment Videos
[Clinical evaluation of imipenem/cilastatin sodium in children]
Insights
MK-0787/MK-0791 demonstrated 75% efficacy in treating pediatric bacterial infections, showing promise as a valuable antibiotic for children. Pharmacokinetic studies revealed favorable half-lives and urinary recovery rates for both drugs.
Area of Science:
- Infectious Diseases
- Pharmacology
- Pediatrics
Context:
- Bacterial infections pose significant risks in pediatric populations.
- Novel antibiotic development is crucial for combating resistant pathogens.
- Intravenous administration is often necessary for severe pediatric infections.
Purpose:
- To evaluate the clinical efficacy and safety of MK-0787/MK-0791 in pediatric patients with moderate to severe bacterial infections.
- To assess the pharmacokinetic profile of MK-0787/MK-0791 following intravenous administration in pediatric patients.
Summary:
- Nine pediatric patients with bacterial infections received MK-0787/MK-0791 intravenously.
- Clinical effectiveness was observed in 75% of cases, with excellent or good outcomes in 6 out of 9 patients.
- Pharmacokinetic analysis in two patients showed mean half-lives of 1.03 hours for MK-0787 and 0.69 hours for MK-0791, with high urinary recovery rates.
Impact:
- MK-0787/MK-0791 shows potential as an effective antibiotic for pediatric bacterial infections.
- Understanding the pharmacokinetics aids in optimizing dosing regimens for pediatric use.
- This study contributes to the evidence base for novel antibiotic therapies in pediatric practice.
Abstract:
Nine pediatric patients with moderate or severe bacterial infections (3 septicemia or bacteremia, 2 pyelitis, 2 tonsillitis, 1 pneumonia and 1 pyothorax) in hospital were treated with MK-0787/MK-0791. The drug was administered intravenously by 30 or 60 minutes drip infusion in 3 or 4 divided doses totalling 24 mg/24 mg-70.2 mg/70.2 mg per kg/day. Clinical effectiveness were excellent in 4 cases, good in 2 cases, poor in 2 cases and not evaluated in 1 case. The overall efficacy rate was 75%. A slight decrease of WBC was observed in 1 case. It was concluded that MK-0787/MK-0791 was a useful antibiotic for the treatment of infections in pediatric practices. Pharmacokinetics of intravenously administered MK-0787/MK-0791 was studied in 2 other cases. The MK-0787/MK-0791 was administered intravenously by 30 or 60 minutes drip infusion to 2 cases at a dose of 10 mg/10 mg/kg. The mean half-life (T1/2) of MK-0787 was 1.03 hours and MK-0791, 0.69 hour. The mean urinary recovery rate of MK-0787 within 6.5-7 hours after administration was 62.5% and MK-0791, 76.7%.